Treatment of @entity46 by vaginal administration of XXXX .

@entity1 @entity19857 @entity1834 @entity28696 @entity46 @entity1017 @entity546 @entity2588
The effectiveness and acceptability of @entity28696 administered by vaginal route was evaluated in a group of 110 @entity1 with @entity46 . @entity1 were divided into four groups. The first three groups were treated by vaginal route. Group I (n = 17) received two 2.5-mg tablets weekly; group II (n = 31) received three 2.5-mg tablets weekly; group III (n = 35) received two 5.0-mg tablets weekly. Group IV consisted of 27 @entity1 who received 2.5 mg of @entity28696 orally twice weekly. Ninety-eight @entity1 completed the 6- to 8-month treatment period. @entity2588 developed in all treatment groups, including group I (34%). The disappearance of both @entity546 and @entity1834 occurred in most @entity1 in all treatment groups soon after the second month of therapy. @entity1 treated by vaginal route had significantly less @entity19857 and acne than those treated by oral route. @entity1017 was also significantly less in vaginally treated @entity1 than in those treated orally. Pregnancy rate following discontinuation was not significantly different for the various groups.
